|
|
|
|
| LEADER |
00000cam a2200000 7i4500 |
| 001 |
0000092147 |
| 005 |
20200311093000.0 |
| 008 |
170601s2017 ne eng |
| 020 |
|
|
|a 9780128025765
|
| 040 |
|
|
|a UniSZA
|e rda
|
| 050 |
0 |
0 |
|a RC271.C5
|b A58 2017
|
| 060 |
1 |
0 |
|a QZ 267
|b .A629 2017
|
| 090 |
0 |
0 |
|a RC271.C5
|b A58 2017
|
| 245 |
0 |
0 |
|a Anti-angiogenesis strategies in cancer therapies
|c edited by Shaker A. Mousa and Paul J. Davis
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier/AP, Academic Press is an imprint of Elsevier
|c c2017
|
| 300 |
|
|
|a xv, 194 pages :
|b illustration(some color) ;
|c 23 cm.
|
| 336 |
|
|
|a text
|2 rdacontent
|
| 337 |
|
|
|a unmediated
|2 rdamedia
|
| 338 |
|
|
|a volume
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references and index
|
| 505 |
0 |
|
|a 1. Angiogenesis and anti-angiogenesis strategies in cancer -- 2. Models for assessing anti-angiogenesis agents: appraisal of current techniques -- 3. Anti-angiogenesis in multiple myeloma -- 4. Interface between Thrombosis-Inflammation and Angiogenesis in cancer progression -- 5. MicroRNAs and Angiogenesis -- 6. Naturally occurring angiogenesis inhibitors -- 7. Integrin antagonists and angiogenesis -- 8. Tyrosine kinase inhibitors and angiogenesis -- 9. Tetraiodothyroacetic acid at integrin avB3: a model of pharmaceutical anti-angiogenesis -- 10. Anti-angiogenesis therapy and its combinations with chemotherapy: impact on primary tumor and its metastasis -- 11. Application of nanotechnology to target tumor angiogenesis in cancer therapeutics -- 12. New directions in anti-angiogenesis research
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy
|
| 650 |
|
0 |
|a Neoplasms
|x Drug therapy
|
| 650 |
|
0 |
|a Neoplasms
|x Therapy
|
| 700 |
1 |
|
|a Davis, Paul J. ,
|e editor ,
|c (Professor of pharmacy)
|
| 700 |
1 |
|
|a Mousa, Shaker A. ,
|e editor
|
| 999 |
|
|
|a 1000169232
|b Book
|c OPEN SHELF (30 DAYS)
|e Tembila Campus
|